They could not have made the drug for patients had they not the necessary authorizations already. But, there is no plan to use them initially and they are clearly not a part of NWBO’s initial plan. I would expect the reason is that there would need to be a plan with space and scale up and equipment set aside and that would be expensive and would in fact go to another company, and spending it on Sawston, in a space the company controls, so that they can develop Flaskworks and improve their manufacturing technology and process patents and lock up this technology is far more important as a business objective. Smaller dollars spent today generate far more leverage over the entire space than big dollars to give to CRL. But CRL can be a part of their expansion plans with the FDA and other regulators as necessary. Making it the core manufacturing space, to me, seems not the right move. It would also all be legacy manufacturing, which would be costly and not as helpful to scaling faster as the likely very reasonable process at Sawston to get Flaskworks technology up and running, probably in 2022, most optimistically early in 2022, imho.
Market Data 
Markets 
AI
